AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthe ...

AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 46.67%. A quarter ago, it was expected that this medical device maker would post a loss of $0.20 per share when it actually produced a loss of $0.17, delivering a surprise of 15%.Over the last four quarters, the company has surpa ...

Financial Results - AtriCure announced preliminary financial results for Q4 and full year 2024 on January 13, 2025[4] Investor Relations - The company is holding investor meetings to discuss business and growth strategy during the week of January 13, 2025[6] Forward-Looking Statements - The press release and investor presentation contain forward-looking statements regarding future performance and are subject to risks and uncertainties[7]

Core Insights - Analysts project AtriCure (ATRC) will report a quarterly loss of $0.15 per share, reflecting a 28.6% increase year over year, with revenues expected to reach $124.3 million, a 16.7% increase from the same quarter last year [1] Revenue Estimates - The consensus estimate for 'United States Revenue- Pain management' is $16.48 million, indicating a year-over-year change of +27.2% [4] - Analysts estimate 'United States Revenue- Total ablation' at $60.11 million, suggesting a +13.6% change from the prior-year quarter [4] - 'International Revenue- Total ablation' is projected to reach $13.30 million, reflecting a +19.6% year-over-year change [4] - The average prediction for 'United States Revenue- Total' stands at $99.69 million, indicating a +12.3% change year over year [5] - 'International Revenue- Appendage management' is expected to be $8.45 million, showing a +26.7% increase from the year-ago quarter [5] - 'United States Revenue- Open ablation' is forecasted to reach $31.84 million, indicating a +16.7% year-over-year change [5] - 'International Revenue- Open ablation' is estimated at $9.53 million, reflecting a +12.6% change from the year-ago quarter [6] - 'United States Revenue- Minimally invasive ablation' is projected to be $11.79 million, indicating a -7% change year over year [6] - 'United States Revenue- Appendage management' is expected to be $39.55 million, suggesting a +10.4% year-over-year change [7] - 'International Revenue- Total' is forecasted to reach $21.74 million, indicating a +22.2% change year over year [7] Stock Performance - AtriCure shares have increased by +22.2% over the past month, outperforming the +4.2% move of the Zacks S&P 500 composite [8] - AtriCure holds a Zacks Rank 3 (Hold), indicating expectations to mirror overall market performance in the near future [8]

Wall Street expects a year-over-year increase in earnings on higher revenues when AtriCure (ATRC) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 12. ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 par value ATRC NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________ FORM 10-Q ___________________________________________________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ...

AtriCure, Inc. (NASDAQ:ATRC) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call. This call is being recorded for replay purpos ...

For the quarter ended September 2024, AtriCure (ATRC) reported revenue of $115.91 million, up 17.9% over the same period last year. EPS came in at -$0.17, compared to -$0.20 in the year-ago quarter. The reported revenue represents a surprise of +2.95% over the Zacks Consensus Estimate of $112.59 million. With the consensus EPS estimate being -$0.20, the EPS surprise was +15.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...

AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15%. A quarter ago, it was expected that this medical device maker would post a loss of $0.15 per share when it actually produced a loss of $0.17, delivering a surprise of -13.33%. Over the last four quarters, the company has su ...

Exhibit 99.1 For immediate release October 29, 2024 AtriCure Reports Third Quarter 2024 Financial Results • Worldwide revenue of $115.9 million – an increase of 17.9% year over year • U.S. revenue of $95.5 million – an increase of 16.8% year over year • Achieved 20% growth on revenues from open appendage management devices in the U.S. • International revenue of $20.5 million – an increase of 23.3% year over year • Positive cash flow generation of $16.3 million in third quarter 2024 MASON, Ohio, October 29, ...